Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Advances in Lung Cancer: Highlights Webinar by VJOncology
Featuring presentations & expert discussions on the latest breakthroughs and clinical developments in lung cancer, with a focus on data and updates from recent international meetings, including ELCC, ASCO, WCLC, and ESMO 2025.
Chair: Sanjay Popat | Moderators: Mariana Brandao, Gregory Riely
The Advances in Lung Cancer 2025 Highlights Webinar was supported by Johnson and Johnson (Platinum supporter) and Regeneron (Silver supporter). AstraZeneca has provided a sponsorship grant towards this independent programme. Supporters have no influence over the production of content.
Evolving treatment strategies for EGFRm NSCLC
Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study (Abstract 4O - ELCC)
James Chih-Hsin Yang National Taiwan University, Taipei, Taiwan, Province of China
Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Early success of the COCOON trial (Abstract 10MO - ELCC)
Nicolas Girard Curie Institute, Paris, France
COMPEL: Osimertinib + platinum-based chemotherapy in patients with EGFRm advanced NSCLC and progression on 1L osimertinib (Abstract OA08.03 - WCLC)
Nir Peled University of Padova, Padova, Italy
PALOMA-2: Subcutaneous amivantamab administered 4very 4 Weeks (Q4W) Plus Lazertinib in First-Line EGFR-Mutated Advanced NSCLC (Abstract MA08.05 - WCLC)
Nicolas Girard Curie Institute, Paris, France
Panel discussion 1
Latest with checkpoint inhibitors & TKIs for HER2m and ROS+ NSCLC
Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816 (Abstract LBA8000 - ASCO)
Patrick Forde Trinity St. James's Cancer Institute, Dublin, Ireland
Pivotal ARROS-1 efficacy and safety data: Zidesamtinib in TKI pre-treated patients with advanced/metastatic ROS1+ NSCLC (Abstract PL02.15 - WCLC)
Ross Camidge University of Colorado, CO, United States
Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study (Abstract LBA75 - ESMO)
Nicolas Girard Curie Institute, Paris, France
Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG 1 (Abstract LBA74 - ESMO)
Sanjay Popat The Royal Marsden NHS Foundation Trust, London, United Kingdom
Panel discussion 2
Advances in SCLC and high-risk NSCLC treatment
An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay (Abstract LBA8027 - ASCO)
Johannes Kratz Sarah Cannon Research Insitute, Nashville, TN, United States
Johannes Kratz
Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study (Abstract 2757O - ESMO)
Mor Moskovitz Davidoff Cancer Center, Petah Tikva, Israel
Panel discussion 3
